Pharma stocks showed strength on Thursday, defying market weakness. Dr Reddy's Laboratories saw significant gains, fueled by anticipation o...

Global demand for weight-loss drugs Ozempic and Wegovy has caused semaglutide prices to drop significantly. Manufacturing has expanded rapi...

Mounjaro, the star pharmaceutical from Eli Lilly, is experiencing a downturn in sales across India. This slump can be attributed to competi...

Pharma stocks fell Thursday after reports of US President Donald Trump mulling 100% tariffs on imported branded and patented medicine maker...

Danish drugmaker Novo Nordisk is set to launch its popular diabetes drug Ozempic in India this month. This move aims to capture a significa...

Wockhardt’s breakthrough respiratory drug Zaynich moves a step closer to market as the US FDA accepts it for review, boosting approval odds...

Systematix Group's Vishal Manchanda anticipates Q4 results for pharma companies to align with previous quarters, with high single-digit dom...

Indian drugmakers are seeking bilateral discussions with the U.S. to avoid President Donald Trump’s proposed 25% tariff on pharmaceutical i...

US tariffs on pharmaceutical imports will affect India’s pharma sector, a leader in affordable generics. Analyst Vishal Manchanda highlight...

Vishal Manchanda highlights the potential challenges the pharmaceutical sector may face in FY27 due to reliance on key drugs and weak US bu...

So I would say US has started to move on a positive trajectory. Earlier it was on a declining trajectory and a cause of concern for most co...

Stocks such as Divi's Laboratories, Ipca, Dr Reddy's, Cipla, and Alkem Laboratories have gained between 2% and 4% in the past week. The sec...

Manchanda added that the anti-infectives treating HIV, TB and drug cessation treatments in the list doesn't have a major impact on margins ...

“Aurobindo injectable business can trade at up to 35x valuation. Aurobindo’s current trading multiple is around 10x. So there is a large up...

‘On a very conservative basis, the drug can add about $300 million to their sales in FY23-FY24.’

US will continue to dominate and order impact could be diluted once the names of the drugs that can be imported come out.

Analyst who ET spoke to said the management expressed confidence that an escalation would not happen.